Human Infection Challenge with Serotype 3 Pneumococcus.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

1. Comprehensive review of safety in Experimental Human Pneumococcal Challenge.PloS one · 2023
   Pooled it
2. Distribution ofVaccines · 2026
   Review
3. Kinetic profile and mucosal capsular polysaccharide IgG responses to serotype 3 pneumococcus in the adult oropharynx following an experimental human challenge.Frontiers in microbiology · 2026
   Article
4. Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigateBMJ open · 2025
   Article
5. Role of the upper airway microbiota in respiratory virus and bacterial pathobiont dynamics in the first year of life.Nature communications · 2025
   Article
6. Antibodies against polysaccharide type 3 and pneumococcal proteins demonstrate synergistic protective effect in a highly virulent type 3 invasive disease model in mice.Frontiers in immunology · 2025
   Article
7. An oropharyngeal gonorrhoea controlled human infection model: a provisional protocol using a novelWellcome open research · 2025
   Article
8. Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction.The Journal of infectious diseases · 2024
   Article
9. Antibody responses after sequential vaccination with PCV13 and PPSV23 in patients with moderate to severe plaque psoriasis under immunosuppressive therapy.mBio · 2024
   Article
10. Serotype 3 Experimental Human Pneumococcal Challenge (EHPC) study protocol: dose ranging and reproducibility in a healthy volunteer population (challenge 3).BMJ open · 2024
    Article
11. Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022.Immunotherapy advances · 2023
    Review
12. An Experimental Human Colonization Model with Pneumococcal Serotype 3 has the Potential to be Used for Vaccine Studies.American journal of respiratory and critical care medicine · 2022
    Article

Corrections and comments

• Commented on by
  An Experimental Human Colonization Model with Pneumococcal Serotype 3 has the Potential to be Used for Vaccine Studies.2022

Authors and funding

34 authors at 3 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as